secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001171843-25-005235
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2
--------------------------------------------------------------------------------

- Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.
- Operating expenses flat at $1.9M; R&D $0.9M, G&A $1.0M.
- Cash and cash equivalents $12.4M, working capital $12.1M at June 30, 2025.
- EB06 Phase 2 vitiligo IND data submission to FDA planned by end of calendar 2025; manufacturing activities ongoing.
- EB05 program benefits from fully funded U.S. government platform study; first randomizations completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/0001171843-25-005235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/f8k_080825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer